Found: 27
Select item for more details and to access through your institution.
Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials.
- Published in:
- Current Oncology, 2024, v. 31, n. 9, p. 5498, doi. 10.3390/curroncol31090407
- By:
- Publication type:
- Article
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1713, doi. 10.3390/cancers11111713
- By:
- Publication type:
- Article
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
- Published in:
- Cancers, 2018, v. 10, n. 6, p. 205, doi. 10.3390/cancers10060205
- By:
- Publication type:
- Article
Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia.
- Published in:
- Annals of Internal Medicine, 2003, v. 139, n. 12, p. 996, doi. 10.7326/0003-4819-139-12-200312160-00009
- By:
- Publication type:
- Article
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2023, v. 28, n. 9, p. 812, doi. 10.1093/oncolo/oyad073
- By:
- Publication type:
- Article
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
- Published in:
- Lipids in Health & Disease, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12944-015-0006-5
- By:
- Publication type:
- Article
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 1, p. e2352302, doi. 10.1001/jamanetworkopen.2023.52302
- By:
- Publication type:
- Article
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 6, p. e2319607, doi. 10.1001/jamanetworkopen.2023.19607
- By:
- Publication type:
- Article
IN DEFENSE OF THE INTERNATIONAL TREATY ARBITRATION SYSTEM.
- Published in:
- Houston Journal of International Law, 2008, v. 31, n. 1, p. 47
- By:
- Publication type:
- Article
β<sub>3</sub>-Adrenergic Receptor-Mediated Lipolysis and Oxygen Consumption in Brown Adipocytes from Cynomolgus Monkeys.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 1997, v. 82, n. 2, p. 395, doi. 10.1210/jcem.82.2.3738
- By:
- Publication type:
- Article
Type Specimens Held in the Fungal, Lichen, and Myxomycete Collections of the University of North Carolina at Chapel Hill Herbarium (NCU).
- Published in:
- Southeastern Naturalist, 2024, v. 23, n. 2, p. 245, doi. 10.1656/058.023.0210
- By:
- Publication type:
- Article
Oncology education for family medicine residents: a national needs assessment survey.
- Published in:
- BMC Medical Education, 2020, v. 20, n. 1, p. N.PAG, doi. 10.1186/s12909-020-02207-0
- By:
- Publication type:
- Article
Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.
- Published in:
- Current Oncology, 2023, v. 30, n. 12, p. 10396, doi. 10.3390/curroncol30120757
- By:
- Publication type:
- Article
Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab.
- Published in:
- Current Oncology, 2022, v. 29, n. 10, p. 7695, doi. 10.3390/curroncol29100608
- By:
- Publication type:
- Article
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma.
- Published in:
- Current Oncology, 2021, v. 28, n. 6, p. 4542, doi. 10.3390/curroncol28060385
- By:
- Publication type:
- Article
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.
- Published in:
- Current Oncology, 2021, v. 28, n. 5, p. 4213, doi. 10.3390/curroncol28050357
- By:
- Publication type:
- Article
Trends in drug revenue among major pharmaceutical companies: A 2010‐2019 cohort study.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 2, p. 311, doi. 10.1002/cncr.33934
- By:
- Publication type:
- Article
Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 1, p. e2253438, doi. 10.1001/jamanetworkopen.2022.53438
- By:
- Publication type:
- Article
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 12, p. e2245596, doi. 10.1001/jamanetworkopen.2022.45596
- By:
- Publication type:
- Article
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1385425
- By:
- Publication type:
- Article
Current immunotherapeutic Strategies to enhance Oncolytic virotherapy.
- Published in:
- Frontiers in Oncology, 2017, p. 1, doi. 10.3389/fonc.2017.00114
- By:
- Publication type:
- Article
Digital Storytelling in Museums: Observations and Best Practices.
- Published in:
- Curator, 2011, v. 54, n. 4, p. 461, doi. 10.1111/j.2151-6952.2011.00110.x
- By:
- Publication type:
- Article
Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 8, p. 2618, doi. 10.1002/cam4.3784
- By:
- Publication type:
- Article
Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 13, p. 4640, doi. 10.1002/cam4.3116
- By:
- Publication type:
- Article
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1379056
- By:
- Publication type:
- Article